

FILE 'CAPLUS' ENTERED AT 16:22:07 ON 07 AUG 2003  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 7 Aug 2003 VOL 139 ISS 6  
FILE LAST UPDATED: 6 Aug 2003 (20030806/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> macrocyclic  
18359 MACROCYCLIC  
84 MACROCYCLICS  
L11 18390 MACROCYCLIC  
(MACROCYCLIC OR MACROCYCLICS)

=> serine()protease()inhibitor  
90472 SERINE  
1452 SERINES  
91032 SERINE  
(SERINE OR SERINES)  
76425 PROTEASE  
28810 PROTEASES  
89502 PROTEASE  
(PROTEASE OR PROTEASES)  
418585 INHIBITOR  
441774 INHIBITORS  
679145 INHIBITOR  
(INHIBITOR OR INHIBITORS)  
L12 2794 SERINE(W) PROTEASE(W) INHIBITOR

=> hepatitis()C()virus  
39020 HEPATITIS  
3061941 C  
285727 VIRUS  
61717 VIRUSES  
296084 VIRUS  
(VIRUS OR VIRUSES)  
L13 8183 HEPATITIS(W) C(W) VIRUS

=> 11 and 12 and 13  
18359 MACROCYCLIC  
84 MACROCYCLICS  
18390 MACROCYCLIC

```

(MACROCYCLIC OR MACROCYCLICS)
0 COMPOUNDS
0 MACROCYCLIC(W) COMPOUNDS
18359 MACROCYCLIC
84 MACROCYCLICS
18390 MACROCYCLIC
(MACROCYCLIC OR MACROCYCLICS)
753760 COMPOUNDS
1500776 COMPDS
1895912 COMPOUNDS
(COMPOUNDS OR COMPDS)
5256 MACROCYCLIC(W) COMPOUNDS
718326 13
L14 0 L1 AND L2 AND 13

```

```

=> 12 and 13
18359 MACROCYCLIC
84 MACROCYCLICS
18390 MACROCYCLIC
(MACROCYCLIC OR MACROCYCLICS)
753760 COMPOUNDS
1500776 COMPDS
1895912 COMPOUNDS
(COMPOUNDS OR COMPDS)
5256 MACROCYCLIC(W) COMPOUNDS
2 HEPETITIS
3061941 C
1 HEPETITIS(W) C
L15 0 L2 AND L3

```

```

=> 111 and 112 and 113
L16 2 L11 AND L12 AND L13

```

=> d all 1-2

```

L16 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2003 ACS on STN
AN 2001:798207 CAPLUS
DN 135:344735
TI Preparation of macrocyclic NS3-serine protease
inhibitors of hepatitis C virus
comprising alkyl and aryl alanine p2 moieties
IN Venkatraman, Srikanth; Chen, Kevin X.; Arasappan, Ashok; Njoroge, F.
George; Girijavallabhan, Viyyoor M.; Chan, Tin-Yau; McKittrick, Brian A.;
Prongay, Andrew J.; Madison, Vincent S.
PA Schering Corporation, USA
SO PCT Int. Appl., 218 pp.
CODEN: PIXXD2
DT Patent
LA English
IC ICM C07D273-00
CC 34-3 (Amino Acids, Peptides, and Proteins)
Section cross-reference(s): 1, 7, 63

```

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001081325	A2	20011101	WO 2001-US12530	20010417
	WO 2001081325	A3	20020801		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,

CO, CR, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, HR, HU, ID,  
IL, IN, IS, JP, KG, KR, KZ, LC, LK, LR, LT, LU, LV, MA, MD, MG,  
MK, MN, MX, MZ, NO, NZ, PL, PT, RO, RU, SE, SG, SI, SK, SL, TJ,  
TM, TR, TT, TZ, UA, UZ, VN, YU, ZA, AM, AZ, BY, KG, KZ, MD, RU,  
TJ, TM

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,  
DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF,  
BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

US 2002016294	A1	20020207	US 2001-836636	20010417
BR 2001010104	A	20030107	BR 2001-10104	20010417
EP 1274724	A2	20030115	EP 2001-927142	20010417

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,  
IE, SI, LT, LV, FI, RO, MK, CY, AL, TR



NO 2002005030	A	20021218	NO 2002-5030	20021018
---------------	---	----------	--------------	----------

PRAI	US	2000-198204P	P	200000419
------	----	--------------	---	-----------

WO 2001-US12530	W	20010417
-----------------	---	----------

OS MARPAT 135:344735

GI



II

AB **Macrocyclic** compds. I [E, X, Y may be independently present or absent, and if present may be (un)substituted (cyclo)alkyl, aryl, heteroalkyl, heteroaryl, ether, amino, sulfide, sulfone, amide, sulfonamide, urea, carbamate, hydrazide, carbonyl, etc.; R1 = acyl or boryl groups; Z = O, N, or CH; W = null, CO, CS, SO2, C:NR (R = H, alkyl, cycloalkyl, aryl, etc.); Q = (NR)p (p = 0-6), O, S, CH2, CHR, CRR' (R' = any group given for R) or a double bond toward V; A = O, CH2, (CHR)p, (CHRCHR')p, (CRR')p, NR, S, SO2, CO or a bond; G = (CH2)p, (CHR)p,

(CRR')p, NR, O, S, SO<sub>2</sub>, SO<sub>2</sub>NH, CO or a bond towards E or V; R<sub>2</sub>, R<sub>3</sub>, R<sub>4</sub> = H, (un)substituted (hetero)alkyl, -aryl or -cycloalkyl, alkoxy, aryloxy, alkylthio, arylthio, amino, amido, ester, carboxylic acid, carbamate, urea, ketone, aldehyde, cyano, nitro, etc.], including enantiomers and pharmaceutically acceptable salts, were prepd. as **hepatitis C virus (HCV) protease inhibitors**. Thus, peptide II was prepd. by a multistep procedure involving cyclization of intermediate cyclopentadiene- $\epsilon$ -6-ruthenium-4-chlorophenylpropionic acid-cyclohexylglycine-m-tyrosine-OMe. II showed  $K_i = 0.001-1.0 \mu M$  in the HCV protease assay. The invention also discloses pharmaceutical compns. comprising I as well as methods of using them to treat disorders assocd. with the HCV protease.

ST **macrocyclic peptide prepn NS3 serine protease inhibitor; hepatitis C treatment macrocyclic peptide**  
IT Hepatitis

(C; prepn. of **macrocyclic NS3-serine protease inhibitors of hepatitis C virus**)

IT Peptides, preparation

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(cyclic; prepn. of **macrocyclic NS3-serine protease inhibitors of hepatitis C virus**)

IT 371110-87-1P 371110-89-3P 371110-91-7P 371110-93-9P 371110-95-1P  
371110-97-3P 371110-99-5P 371111-01-2P 371111-03-4P 371111-08-9P  
371111-09-0P 371111-11-4P 371111-13-6P 371111-15-8P 371111-17-0P  
371111-19-2P 371111-23-8P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(prepn. of **macrocyclic NS3-serine protease inhibitors of hepatitis C virus**)

IT 371110-88-2P 371110-90-6P 371110-92-8P 371110-94-0P 371110-96-2P  
371110-98-4P 371111-00-1P 371111-02-3P 371111-04-5P 371111-05-6P  
371111-06-7P 371111-07-8P 371111-10-3P 371111-12-5P 371111-14-7P  
371111-16-9P 371111-18-1P 371111-20-5P 371111-21-6P 371111-22-7P  
371111-24-9P 371111-25-0P 371111-26-1P 371111-27-2P 371111-28-3P  
371111-29-4P 371111-30-7P 371111-31-8P 371111-32-9P 371111-33-0P  
371111-34-1P 371111-35-2P 371111-36-3P 371111-37-4P 371111-38-5P  
371111-39-6P 371111-40-9P 371112-25-3P 371112-26-4P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of **macrocyclic NS3-serine protease inhibitors of hepatitis C virus**)

IT 149885-80-3

RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)

(prepn. of **macrocyclic NS3-serine protease inhibitors of hepatitis C virus**)

IT 298-12-4, Glyoxylic acid 627-00-9, 4-Chlorobutyric acid 627-05-4,  
1-Nitrobutane 821-41-0, 5-Hexen-1-ol 867-13-0, Triethyl  
phosphonoacetate 1119-60-4, 6-Heptenoic acid 1745-17-1 2019-34-3  
3601-66-9 6282-88-8, Benzenepropanol, 4-chloro- 7389-87-9  
30515-28-7, 7-Bromoheptanoic acid 34087-14-4 68090-88-0 80049-61-2

123053-23-6

RL: RCT (Reactant); RACT (Reactant or reagent)

(prepn. of **macrocyclic NS3-serine protease inhibitors of hepatitis C virus**)

IT	3710-42-7P	14565-11-8P	55478-55-2P	75677-02-0P	161725-12-8P
	166196-05-0P	166196-06-1P	172035-28-8P	228404-10-2P	236393-88-7P
	367258-42-2P	367258-43-3P	367258-44-4P	367258-45-5P	367258-46-6P
	367258-47-7P	367258-48-8P	367258-49-9P	367259-26-5P	367259-52-7P
	367260-51-3P	368454-24-4P	368454-26-6P	371111-41-0P	371111-42-1P
	371111-43-2P	371111-44-3P	371111-45-4P	371111-46-5P	371111-47-6P
	371111-48-7P	371111-49-8P	371111-50-1P	371111-51-2P	371111-52-3P
	371111-53-4P	371111-54-5P	371111-55-6P	371111-56-7P	371111-57-8P
	371111-58-9P	371111-59-0P	371111-60-3P	371111-61-4P	371111-62-5P
	371111-63-6P	371111-64-7P	371111-65-8P	371111-66-9P	371111-67-0P
	371111-68-1P	371111-69-2P	371111-70-5P	371111-71-6P	371111-72-7P
	371111-73-8P	371111-74-9P	371111-75-0P	371111-76-1P	371111-77-2P
	371111-78-3P	371111-79-4P	371111-80-7P	371111-81-8P	371111-82-9P
	371111-83-0P	371111-84-1P	371111-85-2P	371111-86-3P	371111-87-4P
	371111-88-5P	371111-89-6P	371111-90-9P	371111-91-0P	371111-92-1P
	371111-93-2P	371111-94-3P	371111-95-4P	371111-96-5P	371111-97-6P
	371111-98-7P	371111-99-8P	371112-00-4P	371112-01-5P	371112-02-6P
	371112-03-7P	371112-04-8P	371112-05-9P	371112-07-1P	371112-08-2P
	371112-09-3P	371112-10-6P	371112-11-7P	371112-12-8P	371112-13-9P
	371112-14-0P	371112-15-1P	371112-16-2P	371112-17-3P	371112-18-4P
	371112-19-5P	371112-20-8P	371112-21-9P	371112-22-0P	371112-23-1P
	371112-24-2P	371241-12-2P	371241-14-4P	371241-18-8P	371241-24-6P
	371241-28-0P	371241-36-0P	371241-43-9P	371241-46-2P	371241-50-8P
	371241-54-2P	371755-64-5P	371755-65-6P		

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(prepn. of **macrocyclic NS3-serine protease inhibitors of hepatitis C virus**)

IT 371112-06-0P

RL: SPN (Synthetic preparation); PREP (Preparation)

(prepn. of **macrocyclic NS3-serine protease inhibitors of hepatitis C virus**)

L16 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2003 ACS on STN

AN 2001:763001 CAPLUS

DN 135:318715

TI Preparation of **macrocyclic NS3-serine protease inhibitors of hepatitis C virus**  
comprising n-cyclic p2 moieties

IN Chen, Kevin X.; Arasappan, Ashok; Venkatraman, Srikanth; Parekh, Tejal N.; Gu, Haining; Njoroge, F. George; Girijavallabhan, Viyyoor M.; Ganguly, Ashit; Saksena, Anil; Jao, Edwin; Yao, Nanhua H.; Prongay, Andrew J.; Madison, Vincent S.; Vibulbhan, Bancha

PA Schering Corporation, USA

SO PCT Int. Appl., 402 pp.

CODEN: PIXXD2

DT Patent

LA English

IC ICM C07D498-00

CC 34-3 (Amino Acids, Peptides, and Proteins)

Section cross-reference(s): 1, 63

FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	----	-----	-----	-----

PI WO 2001077113 A2 20011018 WO 2001-US10869 20010403  
 WO 2001077113 A3 20020620  
 W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,  
 CO, CR, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, HR, HU, ID,  
 IL, IN, IS, JP, KG, KR, KZ, LC, LK, LR, LT, LU, LV, MA, MD, MG,  
 MK, MN, MX, MZ, NO, NZ, PL, PT, RO, RU, SE, SG, SI, SK, SL, TJ,  
 TM, TR, TT, TZ, UA, UZ, VN, YU, ZA, AM, AZ, BY, KG, KZ, MD, RU,  
 TJ, TM  
 RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,  
 DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF,  
 BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG  
 US 2002107181 A1 20020808 US 2001-825399 20010403  
 EP 1268525 A2 20030102 EP 2001-926601 20010403  
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,  
 IE, SI, LT, LV, FI, RO, MK, CY, AL, TR  
 BR 2001009861 A 20030610 BR 2001-9861 20010403  
 NO 2002004797 A 20021204 NO 2002-4797 20021004  
 PRAI US 2000-194607P P 20000405  
 WO 2001-US10869 W 20010403  
 OS MARPAT 135:318715  
 GI

\* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT \*

AB Title compds. I [wherein X and Y = independently (cyclo)alkyl, heteroalkyl, (aryl)heteroaryl, alkyl(hetero)aryl, substituted ether, sulfide, sulfone, amide, sulfonamide, urea, carbamate, hydrazide, carbonyl, etc.; R1 = CHO, acyl, or (un)substituted carboxy, carbamoyl, boryl, etc.; Z = O, N, or CH, W = null or CO, CS, or SO<sub>2</sub>; Q = null or CH, N, P, (CH<sub>2</sub>)p, (CHR)p, (CRR')p, O, NR, S, or SO<sub>2</sub>; A = O, CH<sub>2</sub>, (CHR)p, (CHRCHR')p, (CRR')p, NR, S, SO<sub>2</sub>, or a bond; E = CH, N, CR, or a double bond toward A, L, or G; G = null or (CH<sub>2</sub>)p, (CHR)p, or (CRR')p; J = null or CH, CR, O, S, or NR; M = null or O, NR, S, SO<sub>2</sub>, "(CH<sub>2</sub>)p, (CHR)p, (CHRCHR')p, or (CRR')p; p = 0-6; R, R', R<sub>2</sub>, R<sub>3</sub>, and R<sub>4</sub> = independently H, (cyclo)alkyl, alkenyl, heterocycloalkyl, alkoxy, aryloxy, alkylthio, arylthio, amino, amido, ester, carboxylic acid, carbamate, urea, ketone, CHO, CN, NO<sub>2</sub>, O, N, S, P, etc.] were prepd. as **hepatitis C virus** (HCV) protease inhibitors. For example, II (multi-step prepn. given) was cyclized, deesterified, and coupled with III.bul.HCl (prepn. given) to give the **macrocyclic** hydroxyamide intermediate. Oxidn. using Des-Martin reagent followed by flash chromatog. afforded two diastereomers IV in 82% combined yield. The (S)-isomer inhibited NS3-serine protease HeLa/Huh7 co-transfected cells with a K<sub>i</sub> of 2 .mu.M. The invention also discloses pharmaceutical compns. comprising I as well as methods of using them to treat disorders assocd. with the HCV protease.

ST **macrocyclic** peptide prepn NS3 **serine protease inhibitor**; peptide macrocycle prepn hepatitis C treatment  
 IT Hepatitis

(C, treatment; prepn. of **macrocyclic** NS3-**serine protease inhibitors** of **hepatitis C virus** comprising cyclic p2 moieties)

IT Peptides, preparation  
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use);

BIOL (Biological study); PREP (Preparation); USES (Uses)  
(cyclic; prepn. of **macrocyclic NS3-serine protease inhibitors of hepatitis C virus** comprising cyclic p2 moieties)

IT Antiviral agents  
(pharmaceutical compn. component; prepn. of **macrocyclic NS3-serine protease inhibitors of hepatitis C virus** comprising cyclic p2 moieties)

IT Interferons  
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(pharmaceutical compn. component; prepn. of **macrocyclic NS3-serine protease inhibitors of hepatitis C virus** comprising cyclic p2 moieties)

IT Interferons  
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(.alpha., pharmaceutical compn. component; prepn. of **macrocyclic NS3-serine protease inhibitors of hepatitis C virus** comprising cyclic p2 moieties)

IT 36791-04-5, Ribavirin  
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(pharmaceutical compn. component; prepn. of **macrocyclic NS3-serine protease inhibitors of hepatitis C virus** comprising cyclic p2 moieties)

IT 367257-63-4P 367257-64-5P  
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PUR (Purification or recovery); RCT (Reactant); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)  
macrocyclic NS3-serine protease inhibitors of hepatitis C virus comprising cyclic p2 moieties)

IT 367257-21-4P 367257-22-5P 367257-25-8P 367257-26-9P 367257-33-8P  
367257-34-9P 367257-36-1P 367257-37-2P 367257-38-3P 367257-39-4P  
367257-46-3P 367257-47-4P 367257-53-2P 367257-54-3P 367257-73-6P  
367257-80-5P 367257-81-6P 367257-82-7P 367257-83-8P 367257-85-0P  
367257-86-1P 367264-97-9P  
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PUR (Purification or recovery); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
macrocyclic NS3-serine protease inhibitors of hepatitis C virus comprising cyclic p2 moieties)

IT 367257-23-6P 367257-27-0P 367257-40-7P 367257-42-9P 367257-48-5P  
367257-50-9P 367257-51-0P 367257-67-8P 367257-69-0P 367257-84-9P  
367257-87-2P 367257-88-3P  
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)  
macrocyclic NS3-serine protease inhibitors of hepatitis C virus comprising cyclic p2 moieties)

IT 367257-24-7P 367257-28-1P 367257-29-2P 367257-30-5P 367257-31-6P  
367257-32-7P 367257-35-0P 367257-41-8P 367257-43-0P 367257-44-1P

367257-45-2P	367257-49-6P	367257-52-1P	367257-55-4P	367257-56-5P
367257-57-6P	367257-58-7P	367257-59-8P	367257-60-1P	367257-61-2P
367257-62-3P	367257-65-6P	367257-66-7P	367257-68-9P	367257-70-3P
367257-71-4P	367257-76-9P	367257-77-0P	367257-78-1P	367257-79-2P
367257-89-4P	367257-90-7P	367257-91-8P	367257-92-9P	367257-93-0P
367257-94-1P	367257-95-2P	367257-96-3P	367257-97-4P	367257-98-5P
367257-99-6P	367258-00-2P	367258-01-3P	367258-02-4P	367258-03-5P
367258-04-6P	367258-05-7P	367258-06-8P	367258-07-9P	367258-08-0P
367258-09-1P	367258-10-4P	367258-11-5P	367258-12-6P	367258-13-7P
367258-14-8P	367258-15-9P	367258-16-0P	367258-17-1P	367258-18-2P
367258-19-3P	367258-20-6P	367258-21-7P	367258-22-8P	367258-23-9P
367258-24-0P	367258-25-1P	367258-26-2P	367258-27-3P	367258-28-4P
367258-29-5P	367258-30-8P	367258-31-9P	367258-32-0P	367258-33-1P
367258-34-2P	367258-35-3P	367258-36-4P	367258-37-5P	367258-38-6P
367258-39-7P	367258-40-0P	367258-41-1P	368871-07-2P	368871-08-3P
368871-09-4P	368871-10-7P			

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of **macrocyclic NS3-serine protease inhibitors of hepatitis C virus** comprising cyclic p2 moieties)

IT 149885-80-3, NS3 serine protease

RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)

(prepn. of **macrocyclic NS3-serine protease inhibitors of hepatitis C virus** comprising cyclic p2 moieties)

IT	367259-40-3P	367259-41-4P	367259-42-5P	367259-43-6P	367259-44-7P
	367259-45-8P	367259-46-9P	367259-47-0P	367259-48-1P	367259-49-2P
	367259-50-5P	367259-51-6P			

RL: PEP (Physical, engineering or chemical process); SPN (Synthetic preparation); PREP (Preparation); PROC (Process)

(prepn. of **macrocyclic NS3-serine protease inhibitors of hepatitis C virus** comprising cyclic p2 moieties)

IT	98-58-8, 4-Bromobenzenesulfonyl chloride	98-61-3, Pipsyl chloride
	99-06-9, 3-Hydroxybenzoic acid, reactions	107-87-9, 2-Pentanone
	108-46-3, 1,3-Benzenediol, reactions	621-37-4 627-05-4, 1-Nitrobutane
	1013-88-3, Diphenylketimine	1075-49-6, 4-Vinylbenzoic acid 1119-60-4,
	6-Heptenoic acid 1484-26-0	2900-27-8 2905-24-0, 3-
	Bromobenzenesulfonyl chloride	4248-19-5, tert-Butyl carbamate
	4724-10-1 4799-68-2, 3-Benzyloxypropanol	13726-69-7 19721-22-3,
	3-Mercaptopropanol 19790-60-4, 3-Benzyloxypropionaldehyde	27516-53-6,
	Pentenoic acid 32462-30-9	33821-94-2 36805-97-7 39687-95-1, Methyl
	isocyanoacetate 58558-53-5	64187-48-0 74844-93-2 77530-32-6
	78183-55-8	102195-79-9 103262-83-5 109183-71-3 109183-72-4
	121148-00-3	131721-90-9 161879-12-5 367260-42-2 367260-44-4
	367260-47-7	367260-49-9 367260-51-3 367260-53-5 367260-55-7
	367260-57-9	367260-62-6 367260-64-8 367260-67-1 367260-69-3
	367260-71-7	367260-73-9 367260-76-2 367260-78-4 367260-80-8
	367260-82-0	367260-87-5 367260-90-0 367260-94-4 367260-96-6
	367260-99-9	367261-01-6 367261-07-2 367261-09-4 367261-12-9
	367261-14-1	367261-20-9 367261-22-1 367261-24-3 367261-26-5
	367261-28-7	367261-30-1 367261-32-3 367261-35-6 367261-38-9
	367261-40-3	367261-44-7 367261-46-9 367261-48-1 367261-50-5
	367261-51-6	367261-52-7 367261-54-9 367261-56-1 367261-58-3
	367261-66-3	367261-69-6 367261-71-0 367261-73-2 367261-75-4



368454-24-4 368454-26-6 368871-37-8 368871-38-9 368871-39-0  
368871-40-3 368871-41-4 368871-42-5

RL: RCT (Reactant); RACT (Reactant or reagent)

(prepn. of **macrocyclic NS3-serine protease inhibitors of hepatitis C virus** comprising cyclic p2 moieties)

IT	69651-48-5P	74844-91-0P	84520-67-2P	84740-98-7P	88931-77-5P
	119927-71-8P	166196-05-0P	166196-06-1P	204398-85-6P	367258-42-2P
	367258-43-3P	367258-44-4P	367258-45-5P	367258-46-6P	367258-47-7P
	367258-48-8P	367258-49-9P	367258-50-2P	367258-51-3P	367258-52-4P
	367258-53-5P	367258-54-6P	367258-55-7P	367258-56-8P	367258-57-9P
	367258-58-0P	367258-59-1P	367258-60-4P	367258-61-5P	367258-62-6P
	367258-63-7P	367258-64-8P	367258-65-9P	367258-66-0P	367258-67-1P
	367258-69-3P	367258-70-6P	367258-72-8P	367258-73-9P	367258-75-1P
	367258-77-3P	367258-79-5P	367258-82-0P	367258-83-1P	367258-85-3P
	367258-86-4P	367258-87-5P	367258-88-6P	367258-89-7P	367258-92-2P
	367258-95-5P	367258-97-7P	367258-98-8P	367258-99-9P	367259-01-6P
	367259-02-7P	367259-03-8P	367259-04-9P	367259-05-0P	367259-06-1P
	367259-07-2P	367259-08-3P	367259-09-4P	367259-10-7P	367259-11-8P
	367259-12-9P	367259-13-0P	367259-14-1P	367259-15-2P	367259-16-3P
	367259-17-4P	367259-18-5P	367259-19-6P	367259-20-9P	367259-21-0P
	367259-22-1P	367259-23-2P	367259-24-3P	367259-25-4P	367259-26-5P
	367259-27-6P	367259-28-7P	367259-29-8P	367259-30-1P	367259-31-2P
	367259-32-3P	367259-33-4P	367259-34-5P	367259-35-6P	367259-36-7P
	367259-37-8P	367259-38-9P	367259-39-0P	367259-59-4P	368454-16-4P
	368454-18-6P	368454-20-0P	368454-22-2P	368871-11-8P	368871-12-9P
	368871-13-0P	368871-14-1P	368871-15-2P	368871-16-3P	368871-17-4P
	368871-18-5P	368871-19-6P	368871-20-9P	368871-21-0P	368871-23-2P
	368871-24-3P	368871-25-4P	368871-26-5P	368871-27-6P	368871-28-7P
	368871-29-8P	368871-30-1P	368871-31-2P		

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(prepn. of **macrocyclic NS3-serine protease inhibitors of hepatitis C virus** comprising cyclic p2 moieties)

IT	87691-27-8P	121147-97-5P	121148-05-8P	149507-31-3P	367259-52-7P
	367259-54-9P	367259-56-1P	367259-57-2P	367259-58-3P	367259-60-7P
	367259-61-8P	367259-62-9P	367259-63-0P	367259-64-1P	367259-65-2P
	367259-66-3P	367259-67-4P	367259-68-5P	367259-70-9P	367259-72-1P
	367259-74-3P	367259-76-5P	367259-79-8P	367259-81-2P	367259-85-6P
	367259-87-8P	367259-89-0P	367259-91-4P	367259-93-6P	367259-95-8P
	367259-97-0P	367259-99-2P	367260-01-3P	367260-04-6P	367260-06-8P
	367260-08-0P	367260-10-4P	367260-12-6P	367260-14-8P	367260-15-9P
	367260-17-1P	367260-19-3P	367260-22-8P	367260-24-0P	367260-27-3P
	367260-29-5P	367260-31-9P	367260-33-1P	367260-35-3P	367260-36-4P
	367260-38-6P	367261-83-4P	367264-98-0P	368871-32-3P	368871-33-4P
	368871-34-5P	368871-35-6P	368871-36-7P		

RL: SPN (Synthetic preparation); PREP (Preparation)

(prepn. of **macrocyclic NS3-serine protease inhibitors of hepatitis C virus** comprising cyclic p2 moieties)